Sanuscode Skin Tag Wart Remover

Uses and Indications

This drug is indicated for the removal of common and plantar warts. Common warts are characterized by their rough, “cauliflower-like” appearance on the surface, while plantar warts are specifically located on the bottom of the foot, presenting with tenderness and an interruption of the footprint pattern.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. For optimal results, it is recommended to soak the wart in warm water for approximately 5 minutes. Following this, a sufficient amount of the medication should be applied using a cotton swab to ensure complete coverage of each wart. It is important to allow the application to dry completely.

This procedure may be repeated once or twice daily as necessary, continuing until the wart is removed. Treatment may be administered for a maximum duration of 12 weeks.

Contraindications

Use is contraindicated in the following situations:

Application on irritated skin or any area that is infected or reddened is prohibited due to the potential for exacerbating the condition.

The product should not be applied to moles, birthmarks, warts with hair growth, genital warts, or warts located on the face or mucous membranes, as these areas may be sensitive or require specialized treatment.

Additionally, use is contraindicated in patients with diabetes or poor blood circulation, as these conditions may increase the risk of adverse effects.

Warnings and Precautions

For external use only. In the event of accidental ingestion, immediate medical assistance should be sought by contacting a Poison Control Center at 1-800-222-1222.

This product should not be applied to irritated skin or any areas that exhibit signs of infection or redness. Additionally, it is contraindicated for use on moles, birthmarks, warts with hair growth, genital warts, or warts located on the face or mucous membranes.

Patients with diabetes or those who have poor blood circulation should refrain from using this product due to the increased risk of adverse effects.

If discomfort persists following application, it is imperative to discontinue use and consult a healthcare professional for further evaluation and guidance.

Side Effects

For external use only. Patients are advised to discontinue use and consult a healthcare professional if discomfort persists. This recommendation is crucial to ensure patient safety and to address any underlying issues that may arise during treatment.

Drug Interactions

No specific drug interactions have been identified in the available data. Additionally, there are no reported interactions between the drug and laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on the current information.

Packaging & NDC

Below are the non-prescription pack sizes of Sanuscode Skin Tag Wart Remover (salicylic acid 17% skin tag wart remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should use this product for external application only. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted.

For optimal results, the affected area should be washed prior to application. It is recommended to soak the wart in warm water for 5 minutes before treatment. A cotton swab should be used to apply a sufficient amount of the product to cover each wart, allowing it to dry afterward. This procedure may be repeated once or twice daily as needed, continuing for up to 12 weeks until the wart is removed.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients should be advised that this product is for external use only. It is contraindicated for use on irritated skin or any area that is infected or reddened. Additionally, it should not be applied to moles, birthmarks, warts with hair growing from them, genital warts, or warts on the face or mucous membranes. Caution is warranted in patients with diabetes or poor blood circulation, as these conditions may increase the risk of adverse effects. The safety of this product during pregnancy has not been established, and therefore, pregnant patients should consult their healthcare provider before use.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or lactation considerations. Healthcare professionals should exercise caution and consider the potential risks and benefits when prescribing this medication to lactating mothers. Further research may be necessary to fully understand the implications for breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and if the ingestion was recent.

Furthermore, specific antidotes or treatments may be indicated based on the substance involved in the overdose. Consultation with a poison control center or a medical toxicologist is recommended to guide the management of the patient effectively.

Overall, due diligence in monitoring and supportive care is paramount in managing cases of suspected overdose, even in the absence of specific information regarding the substance in question.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

Skin discoloration has been reported in postmarketing experience, occurring during or after the use of the product. These events have been documented through voluntary reports and surveillance programs.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center at 1-800-222-1222 if the product is swallowed. It is important to inform patients that they should discontinue use and consult a doctor if discomfort persists.

Patients should be cautioned to avoid contact with their eyes. In the event that the product does come into contact with the eyes, they should flush the area with water for at least 15 minutes. Additionally, healthcare providers should emphasize the importance of avoiding inhalation of vapors associated with the product.

Providers should instruct patients to ensure that the product is capped tightly and stored at room temperature, away from heat sources, to maintain its efficacy and safety.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature, ensuring that it is kept away from excessive heat. The storage temperature must not exceed 37°C (99°F) to maintain the integrity of the product. Proper handling and storage conditions are crucial for preserving the quality and efficacy of the product.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Sanuscode Skin Tag Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)